CN1106274A - 抗癌胶囊 - Google Patents
抗癌胶囊 Download PDFInfo
- Publication number
- CN1106274A CN1106274A CN 94101734 CN94101734A CN1106274A CN 1106274 A CN1106274 A CN 1106274A CN 94101734 CN94101734 CN 94101734 CN 94101734 A CN94101734 A CN 94101734A CN 1106274 A CN1106274 A CN 1106274A
- Authority
- CN
- China
- Prior art keywords
- cancer
- radix codonopsis
- poria
- rhizoma atractylodis
- atractylodis macrocephalae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 16
- 239000002775 capsule Substances 0.000 title claims abstract description 16
- 241000756943 Codonopsis Species 0.000 claims description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 241000208340 Araliaceae Species 0.000 claims description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 6
- 235000008434 ginseng Nutrition 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241001446509 Psoralea Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 201000005619 esophageal carcinoma Diseases 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 230000000711 cancerogenic effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000315 carcinogenic Toxicity 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011889 obduction Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种治疗和预防癌症的中成药,其
主要由具有益气健脾、温阳补肾的仙鹤草、黄芪、党
参、补骨脂、白术、茯苓组分组成。本发明配方组成尤
其对食道癌、肺癌、胃癌有明显的疗效。
Description
本发明属于药品,主要涉及的是一种治疗和预防癌症的中成药,尤其对食道癌、肺癌、胃癌有明显的疗效。
癌症是严重危害人类健康的常见多发病之一,据有关方面统计,目前我国平均40秒就有一个人被癌症夺去生命,故有效地治疗和预防癌症已成为医学界重点研究课题和人类的迫切愿望。中医认为:正气亏虚,也就是人体内部环境稳定性及机体内外相对平衡性遭到破坏的时候,致癌因子才能起到作用而导致癌症的形成,并使癌症得以浸润、扩散和转移。癌细胞的转移是癌症的一个凶恶特征,假如没有癌的转移,绝大多数癌症就可以通过手术切除而获得根治,而经血液循环扩散的癌细胞最后能否形成肿瘤取决于人体的免疫功能。据国外资料报道:国外有人将癌细胞移植到健康的“志愿者”身上,经观察,癌细胞并未形成肿瘤,而是很快就被消灭了事实证明,机体的免疫防卫系统参与了癌症的整个发展过程。可以说:人体发生癌症的首要因素是免疫功能低下,各种致癌因素的作用是次要因素。因此,无论是防癌还是治癌,首要的是研究如何提高机体的免疫功能,其次是考虑如何避免或减少与各种致癌因素的接触,人体在致癌因素的长期侵袭下(一般为10年以上),如果免疫力不足,才出现癌前期的病变,从癌前期到癌变也有10年以上的时间。从国外报道的尸体解剖死亡病例后得出的普遍结论是:甲状腺癌的尸解检出率为2%,而临床发病率仅0.0006%,所以说:提高人体的自身免疫力是预防癌症的最好方法,治疗癌症的目的是力争消除患者体内所滋生的癌细胞。目前,西医采用的放疗、化疗、手术等方法均为消除癌细胞,但这些方法副作用大、有效期短、复发率高,究其原因是患者自身免疫力低下。
本发明的宗旨是以扶正为本,以益气健脾、温阳补肾为主,提高人体的免疫功能,增强人体的抗癌能力,促使癌细胞自行萎缩、阻止癌细胞的增殖、扩散和转移,从而提出一种无副作用,可以治疗癌症,又可预防癌症的抗癌胶囊。服用该抗癌胶囊尤其对食道癌、胃癌、肺癌具有明显疗效。
为实现上述宗旨,本发明配方组成主要是以益气健脾、温阳补肾的仙鹤草、黄氏、党参、补骨脂、白术、茯苓组份组成。
本发明的配方组成中,其各组分的含量(重量)范围为:仙鹤草28-50g、黄氏28-60g、党参28-50g、补骨脂47-80g、白术28-50g、茯苓28-50g。
本发明组份中的党参也可采用人参代替,其人参的含量(重量)为:10-20g。
仙鹤草主治劳伤脱力、咳血、吐血,其对S180有杀伤作用。黄氏:主治气虚血脱、脾虚泄泻、盗汗、浮肿,其对S180有抑制作用,促进机体产生干扰素。党参:主治气血两亏、食少、口渴、体倦无力,其药理作用:促进网状内皮系统的吞噬机能,升高白细胞。补骨脂:主治温阳补肾,其药理作用:对S180、EC有抑制作用,有升白细胞作用。白术:主治不思饮食,倦怠少气、虚胀、水肿、头晕,其药理作用:对S180有抑制作用。伏苓:主治水肿、痰饮咳逆。人参:主治劳伤虚损、食少、反胃叶食、自汁暴脱。其药理作用:提高巨噬细胞、吞噬功能,增强机体免疫力。
本发明以保“后天之本”和固“先天之本”为治疗原则,后天之本是指脾胃运化功能,“肾”阴“肾”阳是先天之本,癌症病人常有先天或后天之本不足,是到致癌的内在因素之一。本发明提出的配方组成具有提高机体的免疫功能,增强机体的抗癌能力,促使癌细胞自行萎缩,阻止癌细胞的增殖、扩散和转移。所以说:健脾益气能改善病人的营养吸收,提高病人的细胞免疫功能,改善一般症状。补肾法可以增强癌症病人的细胞免疫功能和免疫监视作用,提高和调节内分泌功能。
本发明的药理研究和毒性研究如下:
药理研究:
抗肿瘤药物体外试验
(1)美蓝试管法:
取食道癌(鳞状上皮癌)、胃癌(腺癌)、直肠癌、肺癌手术切下肿瘤组织各5g、剪碎、研磨成匀浆,分两个刻度管,每管1ml,一管用作试验,一管作对照,加入营养液,抗癌胶囊药液(浓度为10%)37℃卵育后加0.05%美蓝0.1ml37℃,24小时后观察美蓝颜色深浅。
结果:胃癌、食道癌、肺癌、药效阳性,直肠癌药效阴性。
(2)细胞染色法:
取食道癌(鳞状上皮癌)、胃癌(腺癌)直肠癌、肺癌手术切下的肿瘤组织,剪碎、研磨成匀浆,用缓冲液配成细胞悬液(细胞数为10×1012/l)另入抗癌胶囊药液0.1ml(10%浓度)37℃孵育2小时,再加入0.02%伊红染液1分钟,滴入细胞计数池中,显微镜观察细胞着色情况,死细胞着红色,活细胞透亮,反光。
结果:胃癌:被杀伤细胞占40%。
食道癌:被杀伤细胞占35%。
肺癌:被杀伤细胞占32%。
毒性研究:
一、急性毒性试验:
1、半数致死量(LD50)测定:
选择健康的20只大白鼠(雌雄各半),体重480-500g,取抗癌胶囊按5g/只溶解于水中,喂大白鼠,一次喂入。
给药后观察7天,未发现消化系统、呼吸系统、神经系统方面的变异,大白鼠健康。
2、最大耐受量测定:
取小白鼠20只(雌雄各半),体重80-90g,按8g/kg腹腔注入抗癌胶囊药液,一次注入,连续观察7天,20只小白鼠健康。试验用药量相当于临床用药的20倍。
二、长期毒性试验:
选择20只健康的大白鼠(雌雄各半),体重480-500g,按1g/kg量长期喂抗癌胶囊,每日给药一次,连续观察30天,无毒性反应。
经对30例中晚期癌症病人临床治疗,每天给药三次,每次十丸胶囊,连续服药六个月,疗效如下:
治疗人数 | 临床治愈 | 显效 | 有效 | 无效 | 总有效率% |
30 | 1 | 9 | 17 | 3 | 90 |
实施例1
本发明主要由含量(重量)为:
仙鹤草30g、黄氏30g、党参30g、补骨脂50g、白术30g、茯苓30g组份组成,把上述组份混合粉碎后过筛,装零号胶囊而制得。
实施例2
本发明主要由含量(重量)为:仙鹤草35g、黄氏40g、人参15g、补骨脂50g、白术30g、茯苓40g组份组成,把上述组合后粉碎过筛,装零号胶囊制得。
Claims (3)
1、一种抗癌胶囊,其主要由以益气健脾、温阳补肾的仙鹤草、黄氏、党参、补骨脂、白术、茯苓组分组成。
2、根据权利要求1所述的抗癌胶囊,其特征在于:所述的仙鹤草、黄氏、党参、补骨脂、白术、茯苓各组份的含量(重量)范围为:仙鹤草28-50g、黄氏28-60g、党参28-40g、补骨脂47-80g、白术28-50g、茯苓28-50g。
3、根据权利要求1或2所述的抗癌胶囊,其特征在于:所述的党参可采用人参代替,其人参的用量(重量)为10-20g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN94101734A CN1054747C (zh) | 1994-02-05 | 1994-02-05 | 抗癌胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN94101734A CN1054747C (zh) | 1994-02-05 | 1994-02-05 | 抗癌胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1106274A true CN1106274A (zh) | 1995-08-09 |
CN1054747C CN1054747C (zh) | 2000-07-26 |
Family
ID=5030335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94101734A Expired - Fee Related CN1054747C (zh) | 1994-02-05 | 1994-02-05 | 抗癌胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1054747C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1057691C (zh) * | 1997-07-29 | 2000-10-25 | 刘今方 | 一种抗肺癌的中药及其制备方法 |
WO2004045631A1 (fr) * | 2002-11-21 | 2004-06-03 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Utilisation de psoralea corylifolia contre une infection par helicobacter pylori, et pour le traitement des maladies qui resultent d'une telle infection |
CN1813967B (zh) * | 2005-02-02 | 2010-07-14 | 边仪广 | 一种辅助治疗消化道癌症的中成药 |
CN102430086A (zh) * | 2011-12-29 | 2012-05-02 | 湖南九典制药有限公司 | 一种补肾益气的中药组合物及其制备方法 |
CN105056118A (zh) * | 2015-08-05 | 2015-11-18 | 李强 | 一种用于治疗乳腺癌的药物制剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066189A (zh) * | 1991-04-30 | 1992-11-18 | 周纯喜 | 一种抗癌冲剂的制备方法 |
CN1056064C (zh) * | 1993-01-20 | 2000-09-06 | 潘敏求 | 一种治疗肝癌的药物及其制造方法 |
-
1994
- 1994-02-05 CN CN94101734A patent/CN1054747C/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1057691C (zh) * | 1997-07-29 | 2000-10-25 | 刘今方 | 一种抗肺癌的中药及其制备方法 |
WO2004045631A1 (fr) * | 2002-11-21 | 2004-06-03 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Utilisation de psoralea corylifolia contre une infection par helicobacter pylori, et pour le traitement des maladies qui resultent d'une telle infection |
CN1813967B (zh) * | 2005-02-02 | 2010-07-14 | 边仪广 | 一种辅助治疗消化道癌症的中成药 |
CN102430086A (zh) * | 2011-12-29 | 2012-05-02 | 湖南九典制药有限公司 | 一种补肾益气的中药组合物及其制备方法 |
CN105056118A (zh) * | 2015-08-05 | 2015-11-18 | 李强 | 一种用于治疗乳腺癌的药物制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN1054747C (zh) | 2000-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101606632A (zh) | 母猪产期用保健饲料 | |
CN104855979A (zh) | 降血脂非全营养配方食品 | |
CN109966417A (zh) | 一种针对糖尿病人群的固体饮料 | |
CN1054747C (zh) | 抗癌胶囊 | |
CN104305170B (zh) | 一种用于放疗术后调养的中药药膳及其制备方法 | |
CN108210657A (zh) | 一种预防和治疗肺癌的中药组合物 | |
CN103340919B (zh) | 一种灵芝精粉复方软胶囊及其制备方法 | |
CN110522790A (zh) | 一种兼具抗疲劳、提高免疫力和除湿气功效的中药组合物及其制备方法和应用 | |
CN104257883A (zh) | 一种治疗化疗后白细胞减少症的中药组合物 | |
CN104799289A (zh) | 具有抗肿瘤提高免疫功能的复合营养食品及其生产方法 | |
CN108355052B (zh) | 一种治疗放化疗后白细胞降低的药物及其制备方法与应用 | |
CN104430720A (zh) | 黄秋葵、菌、藻植物组合物制作功能性饼干的方法 | |
CN104162093A (zh) | 治疗乳腺癌的中药制剂及其制备方法 | |
CN114177261A (zh) | 一种防治慢性病及抗癌保健的中草药配方 | |
CN103340991B (zh) | 一种用于护理糖尿病患者的口服液及制备方法 | |
CN114748583A (zh) | 一种滋补养生的中药药酒 | |
CN106539981A (zh) | 一种防治肿瘤的复合多糖及其制备方法 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
CN112076305A (zh) | 一种治疗人体代谢症候群及杀菌消炎的中药制内服外用原液合剂 | |
CN107669910A (zh) | 治疗动脉粥样硬化的药物组合物 | |
CN104382007B (zh) | 一种功能性胶囊及其制备方法 | |
CN103689560A (zh) | 一种有助于延年益寿的养生保健食品配方及其制备方法 | |
CN108324783A (zh) | 白归参灵冬甘治癌药 | |
CN109078157A (zh) | 一种抗肿瘤药物及其制备方法 | |
CN102552801A (zh) | 一种用于治疗肿瘤的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Ma Xinsheng Document name: payment instructions |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Ma Xinsheng Document name: payment instructions |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |